29 Nov 2022 --- Nestlé could be potentially divesting its peanut allergy treatment Palforzia following slower than expected adoption by patients and healthcare professionals. Nestlé expects the review to be done in the first half of 2023 and says that Nestlé Health Science will increase its focus on medical nutrition and consumer care.
